Cercar
01/06/2025
AMBISPECTIVE, MULTICENTER REGISTRY OF TREATMENT WITH ANIFROLUMAB IN REAL LIFE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS FROM SPANISH RHEUMATOLOGY DEPARTMENTS (ANIFRO-REU): EFFICACY AND SAFETY AT 3-AND 6-MONTH FOLLOW-UP VISITS
Salman-Monte, TC, Carrion-Barberá, I, Triginer, L, Riveros-Frutos, A, Font, J, Garcia-Villanueva, MJ, Garrote-Corral, S, Galindo, M, Polo, CD, González, IA, Bernabéu, P, Casasempere, PV, Morales, CM, Alvarez, ED, Cortés-Hernández, J, Moreno, SS, Giráldez, CR, Gil, JJF, Hernández, A, Magallares, BP, Garcia, MMP, Cid, CMF, Hernández, S, Ros, I, García-Aparicio, A, Sala-Icardo, L, Gómez-Puerta, JA, Frade-Sosa, B, Garcia-Cirera, S, Bufort, MG, Martínez-Barrio, J, de Salazar, JRG, del Amo, ND, Fito-Manteca, C, Torrente-Segarra, V, Heredia, S, Brandy-Garcia, A, Lucea, ER, Zarrabeitia, LR, Urruticoechea-Arana, A, Pego-Reigosa, JM, Rúa-Figueroa, IJ. AMBISPECTIVE, MULTICENTER REGISTRY OF TREATMENT WITH ANIFROLUMAB IN REAL LIFE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS FROM SPANISH RHEUMATOLOGY DEPARTMENTS (ANIFRO-REU): EFFICACY AND SAFETY AT 3-AND 6-MONTH FOLLOW-UP VISITS. ANNALS OF THE RHEUMATIC DISEASES. 2025; 84DOI:10.1136/annrheumdis-2025-eular.B1338. PMID:. IF:20.600(Q1/1D).
01/06/2025
A comparative analysis of risk stratification tools in SSc-associated pulmonary arterial hypertension: a EUSTAR analysis
Bjorkekjaer, HJ, Bruni, C, Broch, K, Brunborg, C, Carreira, PE, Airò, P, Simeón-Aznar, CP, Truchetet, ME, Giollo, A, Balbir-Gurman, A, Martin, M, Denton, CP, Gabrielli, A, Del Galdo, F, Vonk, MC, Fretheim, H, Bitter, H, Midtvedt,O, Andreassen, A, Hoie, S, Tanaka, Y, Riemekasten, G, Mueller-Ladner, U, Matucci-Cerinic, M, Castellví, I, Siegert, E, Hachulla, E, Molberg,O, Distler, O, Hoffmann-Vold, AM, EUSTAR Collaborators. A comparative analysis of risk stratification tools in SSc-associated pulmonary arterial hypertension: a EUSTAR analysis. RHEUMATOLOGY. 2025; 64(6)DOI:10.1093/rheumatology/keaf053. PMID:39878955. IF:4.400(Q1/1D).
22/04/2025
Platelet-Derived Soluble CD40L and Its Impact on Immune Modulation and Anti-IL6R Antibody Treatment Outcome in Rheumatoid Arthritis
Zamora, C, Diaz-Torne, C, Ortiz, MA, Moya, P, Park, HS, Pitarch, C, Cantó, E, Osuna-Gomez, R, Mulet, M, Garcia-Arguinzonis, M, Collado, D, Corominas, H, Vidal, S. Platelet-Derived Soluble CD40L and Its Impact on Immune Modulation and Anti-IL6R Antibody Treatment Outcome in Rheumatoid Arthritis. Cells. 2025; 14(9)DOI:10.3390/cells14090625. PMID:40358149. IF:5.200(Q2/3D).
28/03/2025
Interindividual variability and its impact on the effectiveness of Janus kinase inhibitors in rheumatoid arthritis treatment
Martinez-Molina, C, Vidal, S, Diaz-Torne, C, Park, HS, Corominas, H. Interindividual variability and its impact on the effectiveness of Janus kinase inhibitors in rheumatoid arthritis treatment. Frontiers in Medicine. 2025; 12DOI:10.3389/fmed.2025.1512501. PMID:40224626. IF:3.000(Q1/2D).